Drugs Today (Barc). 2006 Apr;42(4):255-63.

Ramelteon: profile of a new sleep-promoting medication.

Source

Medical Information Department, Prous Science, Barcelona, Spain. journals@prous.com

Abstract

To date the mainstay of the pharmacological treatment of insomnia has involved the modulation of the gabaminergic system via benzodiazepines or the Z-drugs, zolpidem, zopiclone or zaleplon. A new approach has explored the melatoninergic system, namely activation of MT1 and MT2 receptors in the suprachiasmatic nucleus of the hypothalamus. Ramelteon (TAK-375) is a novel sleep-promoting agent that acts as an agonist at these receptors; its preclinical pharmacology, mode of action, pharmacokinetics, drug interactions, clinical efficacy, and safety and tolerability are reviewed here.

PMID:: 16703122; [PubMed - indexed for MEDLINE]

LinkOut - more resources

Full Text Sources

Prous Science

Other Literature Sources

Labome Researcher Resource - ExactAntigen/Labome

Supplemental Content

Related citations

Review [A novel therapeutic drug: ramelteon]. [Nihon Rinsho. 2009]
Review [A novel therapeutic drug: ramelteon].
Miyamoto M. Nihon Rinsho. 2009 Aug; 67(8):1595-600.
Review Efficacy and clinical safety of ramelteon: an evidence-based review. [Sleep Med Rev. 2008]
Review Efficacy and clinical safety of ramelteon: an evidence-based review.
Sateia MJ, Kirby-Long P, Taylor JL. Sleep Med Rev. 2008 Aug; 12(4):319-32.
Review Pharmacology of ramelteon, a selective MT1/MT2 receptor agonist: a novel therapeutic drug for sleep disorders. [CNS Neurosci Ther. 2009]
Review Pharmacology of ramelteon, a selective MT1/MT2 receptor agonist: a novel therapeutic drug for sleep disorders.
Miyamoto M. CNS Neurosci Ther. 2009 Winter; 15(1):32-51.
Ramelteon 8 mg/d versus placebo in patients with chronic insomnia: post hoc analysis of a 5-week trial using 50% or greater reduction in latency to persistent sleep as a measure of treatment effect. [Clin Ther. 2008]
Ramelteon 8 mg/d versus placebo in patients with chronic insomnia: post hoc analysis of a 5-week trial using 50% or greater reduction in latency to persistent sleep as a measure of treatment effect.
Mini L, Wang-Weigand S, Zhang J. Clin Ther. 2008 Jul; 30(7):1316-23.
Self-reported efficacy and tolerability of ramelteon 8 mg in older adults experiencing severe sleep-onset difficulty. [Am J Geriatr Pharmacother. 2007]
Self-reported efficacy and tolerability of ramelteon 8 mg in older adults experiencing severe sleep-onset difficulty.
Mini LJ, Wang-Weigand S, Zhang J. Am J Geriatr Pharmacother. 2007 Sep; 5(3):177-84.

See reviews... See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.

Recent activity

Clear Turn Off Turn On

Ramelteon: profile of a new sleep-promoting medication.
Ramelteon: profile of a new sleep-promoting medication.
Drugs Today (Barc). 2006 Apr ;42(4):255-63.

PubMed
The evolution of adaptive immune systems.
The evolution of adaptive immune systems.
Cell. 2006 Feb 24 ;124(4):815-22.

PubMed
Dimensional representations of DSM-IV cluster A personality disorders in a popul...
Dimensional representations of DSM-IV cluster A personality disorders in a population-based sample of Norwegian twins: a multivariate study.
Psychol Med. 2006 Nov ;36(11):1583-91. Epub 2006 Aug 8 .

PubMed
L-arginine supplementation improves exercise capacity after a heart transplant.
L-arginine supplementation improves exercise capacity after a heart transplant.
Am J Clin Nutr. 2010 May ;91(5):1261-7. Epub 2010 Mar 3 .

PubMed
Why myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) may kill you: di...
Why myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) may kill you: disorders in the inflammatory and oxidative and nitrosative stress (IO&NS) pathways may explain cardiovascular disorders in ME/CFS.
Neuro Endocrinol Lett. 2009 ;30(6):677-93.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Display Settings:

Send to:

Ramelteon: profile of a new sleep-promoting medication.

Source

Abstract

Publication Types, MeSH Terms, Substances

Publication Types

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Supplemental Content

Related citations

Related information

Recent activity

Simple NCBI Directory

Getting Started

Resources

Popular

Featured

NCBI Information